Strategic Timing of Anti-Retroviral Treatment (START Study)

Project Timeline

2016 – Now

The START trial was designed to address the question: In HIV-1 (subsequently referred to as HIV) infected asymptomatic participants with a CD4+ count greater than 500 cells/mm3, is immediate use of antiretroviral therapy (ART) superior to deferral of ART until the CD4+ count declines to 350 cells/mm3 or AIDS develops in terms of morbidity and mortality? The study is being conducted at 237 sites in 35 countries. Global enrolment closed with 4,688 participants enrolled.

External Links

Kirby Institute – University of New South Wales

Strategic Timing of Antiretroviral Treatment (START) – ClinicalTrials.gov

Events

Other Clinical Research

Strategic Timing of Anti-Retroviral Treatment (START Study)

The START trial was designed to address the question: In HIV-1 (subsequently referred to as HIV) infected asymptomatic participants with a CD4+ count greater than 500 cells/mm3, is immediate use...

Making Drug Treatment Work: Opportunities and Challenges Towards an Evidence and Rights-Based Approach

Compulsory drug detention centers (CDDCs) are common throughout Asia. However, medical treatments for substance use disorders, such as opioid agonist treatment (OAT), are generally unavailable in these settings. In this...

Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D²EFT)

First-line antiretroviral regimens are safe, effective and easily administered (one pill taken once daily). Even so, the annual failure rate is around 10-15% of treated patients. Second-line regimens have a...